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To decipher the molecular basis for RET kinase acti-
vation and oncogenic deregulation, we defined the
temporal sequence of RET autophosphorylation by
label-free quantitative mass spectrometry. Early au-
tophosphorylation sites map to regions flanking the
kinase domain core, while sites within the activation
loop only form at later time points. Comparison with
oncogenic RET kinase revealed that late autophos-
phorylation sites become phosphorylated much
earlier than wild-type RET, which is due to a combi-
nation of an enhanced enzymatic activity, increased
ATP affinity, and surprisingly, by providing a better
intermolecular substrate. Structural analysis of onco-
genic M918T and wild-type RET kinase domains
reveal a cis-inhibitory mechanism involving teth-
ering contacts between the glycine-rich loop, acti-
vation loop, and aC-helix. Tether mutations only
affected substrate presentation but perturbed the
autophosphorylation trajectory similar to oncogenic
mutations. This study reveals an unappreciated role
for oncogenic RET kinase mutations in promoting
intermolecular autophosphorylation by enhancing
substrate presentation.
INTRODUCTION
RET is a receptor tyrosine kinase (RTK) expressed and required
during early development for the formation of neural crest-
derived lineages and kidney organogenesis (Arighi et al., 2005;
Plaza-Menacho et al., 2006). It has been reported, based on
cell-based experimental models, that upon ligand and corecep-
tor binding to the extracellular domain, the catalytic and
signaling activity of RET kinase are controlled by the autophos-phorylation (autoP) of several tyrosine residues within the cyto-
plasmic domain (Airaksinen et al., 1999; Plaza-Menacho et al.,
2006). For other RTK paradigms such as the insulin receptor
and FGFR2, ligand-dependent activation leads to autoP of
specific tyrosine residues to both relieve repressive cis-autoinhi-
bitory interactions and to promote binding of PTB- and SH2-
domain containing proteins that trigger downstream signaling
(Chen et al., 2007; Hubbard, 1997). While the latter role for autoP
has been demonstrated for RET, the effect of autoP on catalytic
activation is less clear. In vitro, activation loop (AL) phosphoryla-
tion has little effect on catalytic activity (Knowles et al., 2006;
Plaza-Menacho et al., 2011). A similar situation is found for the
EGFR and nonreceptor tyrosine kinase ACK1 (Lougheed et al.,
2004; Zhang et al., 2006). In these cases, allosteric mechanisms
have been identified to stimulate receptor activation indepen-
dent of AL phosphorylation status.
The canonical RET-AL between the DFG and APE motifs,
common to RTKs, contains two tyrosine residues, Y900 and
Y905, required for signaling in cells (Kawamoto et al., 2004).
Many RTKs such as the FGFR1 and FGFR2 have two tyrosines
in this region, whose autoP is carefully orchestrated leading to
a precise and sequential order of tyrosine phosphorylation
(Chen et al., 2007, 2008; Furdui et al., 2006; Lew et al., 2009).
For FGFR1, a three-stagemechanism serves to initially stimulate
the intrinsic tyrosine kinase activity and subsequently target tyro-
sine residues both within and outside of the kinase domain (KD)
(Chen et al., 2008; Furdui et al., 2006; Lew et al., 2009). There are
few, if any, studies examining the sequence of RET autoP
(Coulpier et al., 2002). Exhaustive phosphopeptide mapping
and western blots (WB) with antiphosphospecific tyrosine anti-
bodies have identifiedmany of themajor autoP sites but crucially
temporal information is lacking (Kawamoto et al., 2004). An alter-
native way to follow the order of RET autoP (without requiring a
battery of phosphospecific antibodies) is to use label-free quan-
titative mass spectrometry (LFQMS). This approach can simulta-
neously monitor all tyrosine phosphorylation sites by employing
more sensitive fast scanning mass spectrometers that acquire
higher mass accuracy data in tandem with HPLC hardwareMolecular Cell 53, 1–14, March 6, 2014 ª2014 The Authors 1
Figure 1. Early RET AutoP Sites Map to Regions outside the KD Core
(A) Schematic diagram of discrete RET functional domains together with the autoP sites analyzed in this study.
(B) Global temporal autoP analysis by LFQMS of recombinant purified RET ICD (2.5 mM) treated with saturating concentrations of ATP (5 mM) andMgCl2 (10 mM)
for 0–120 min. Data represent the mean signal value (Log2 ratios of phosphorylated peptides standardized to the nonphosphorylated counterparts) ± SE of four
independent experiments (n = 4) performed with different protein preparations.
(C) WB analyses of samples analyzed in (B) using the indicated antibodies.
(D) Phosphorylation status (saturation rate, percentage) for each LFQMS-identified autoP site and phosphorylation state (1P to 6P) from (B).
(E) Cumulative phosphorylation for each autoP site from (D).
See also Figure S1.
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2006). In label-free quantitation, peptide ion abundances are
measured from extracted ion chromatograms and the relative
abundance of integrated ion signals between independent
mass spectometry (MS) runs is compared.
Germline missense activating point mutations in RET cause
the cancer syndrome multiple endocrine neoplasia type 2
(MEN2). How these point mutations, scattered throughout the
RET KD and elsewhere, impact on and subvert intrinsic activa-
tion mechanisms for RET is still not clear (Plaza-Menacho
et al., 2006). Equally, it is not knownwhether such RETmutations
impact on the sequential order of autoP as has been shown for
pathogenic mutations in FGFR1 and FGFR2 (Chen et al., 2008;
Lew et al., 2009).
Here, we combine quantitative proteomics, biochemical anal-
ysis, and X-ray crystallography to define the temporal sequence
of RET autoP (trajectory) and identify intrinsic repressive interac-
tions via a cluster of residues stabilizing an autoinhibited form2 Molecular Cell 53, 1–14, March 6, 2014 ª2014 The Authorsof the kinase. In addition, perturbation of the autoP trajectory
by oncogenic RET kinase mutants uncovered both an enhanced
RET kinase substrate presentation in trans and ATP occupancy
in cis as molecular determinants of oncogenic RET kinase
activation.
RESULTS
Early RET AutoP Sites Map to Flanking Regions outside
the KD Core
To define the precise temporal sequence of RET autoP, we used
purified recombinant RET intracellular domain (ICD; residues
661–1072; Figure 1A) expressed in Sf9 insect cells and
performed in vitro time course autoP assays using saturating
concentrations of ATP (5 mM) and MgCl2 (10 mM) for 0–
120min. Monomeric status and kinase activity of purified soluble
protein were confirmed by size exclusion chromatography and
enzyme kinetics experiments using poly-E4Y peptide (Figure S1
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sessed by LFQMS (Figure 1B). This powerful technique has a
higher dynamic range than isotope labeling methods and allows
us to potentially compare multiple phosphorylation sites and
samples (Cutillas et al., 2005; Steen et al., 2006). We identified
seven tyrosines: Y687, Y826, Y900, Y905, Y1015, Y1029, and
Y1062 that, upon KD activation, became efficiently phosphory-
lated in a time-dependent fashion (Figure 1B). Y826, which ap-
peared to be weakly phosphorylated upon KD activation but
did not change significantly with time was excluded from further
analysis. Signal log2 ratios of phosphorylated peptides standard-
ized to their nonphosphorylated counterparts were plotted rela-
tive to zero time point (Figure 1B). Global autoP analysis revealed
that sites located at the flanking regions were phosphorylated
first; in particular the C-terminal Y1062 followed by the juxta-
membrane Y687 were phosphorylated more rapidly than sites
located within the KD core such us AL Y900 and Y905 (Figures
1B and 1C). A closer examination of the temporal sequence of
RET autoP showed that Y1062 and Y687 followed very fast satu-
ration kinetics, taking between 1–5 min to reach a 25-fold and
50-fold increase in overall phosphorylation levels, respectively.
This contrasted with AL Y900 and Y905 sites, which needed
40–80 min to reach saturation at25-fold and 35-fold increased
phosphorylation levels, respectively (Figures 1B and 1D). Inter-
estingly, we observed that the double phosphorylated peptide
containing both Y900 and Y905 resulted in higher phosphoryla-
tion levels (45-fold increase) together with faster saturation than
the single phosphorylated peptides. Phosphorylation of Y1015
and Y1029 followed very similar kinetics to AL tyrosines, with
the exception of the single phosphorylated peptides, which
were slightly slower. Despite very rapid saturation kinetics for
Y1062 and Y687 (Figure 1D), fully phosphorylated RET was
found only at late time points, (95% phosphorylated by 40 min
and 100%by 80min), suggesting slow allosteric inputs in the au-
toP process (Figure 1E). We validated the results from the
LFQMS by WB analysis using available phosphospecific anti-
bodies (Figure 1C). Interestingly, another tyrosine site within
the KD core Y981, which was not identified by LFQMS, showed
the same tendency as Y905. We also tested a phosphospecific
antibody against Y1015 and observed faster kinetics of autoP
compared to the quantitative mass spectrometry data. An in-
spection of this particular peptide sequence analyzed by LFQMS
indicated it also contained Y1029. We could not explain this
discrepancy at this stage, as the LFQMS data would not discrim-
inate between the two sites in the single phosphorylated peptide
(see Figure 2). Overall, the definition of the temporal sequence of
RET autoP (i.e., trajectory) identifies early sites flanking the RET
KD core (e.g., Y1062 and Y687) and late sites within the AL (e.g.,
Y900 and Y905) and KD consistent with an autoP trajectory
shown in Figure 1D.
To confirm that RET autoP sites generated upon KD activation
came from an intermolecular rather than intramolecular mecha-
nism, time course autoP assays were performed with increasing
concentrations of RET ICD (1 mM, 2.5 mM, and 5 mM, respec-
tively). WB analysis using total and phospho-specific tyrosine
antibodies demonstrated that the degree of autoP was directly
proportional to the concentration of protein employed in the
reaction indicating autoP in trans (Figure S1).Primary Sequence Flanking the Phosphoacceptor
TyrosineDoesNot Determine the Temporal Sequence of
RET AutoP
We compared the consensus sequence of RET autoP sites
obtained by LFQMS, including also Y981 (Figure S2), with that
derived from an optimal RET KD peptide substrate (Plaza-Men-
acho et al., 2011). In addition, enzymatic assays were performed
with RET ICD in both phosphorylated and nonphosphorylated
states against peptides derived from the different autoP sites,
and catalytic efficiency constants (kcat/KM) were determined
(Figure S2). There was poor agreement between these data,
from which we concluded that the precise sequence of RET
autoP is not determined by primary sequence flanking the
phosphoacceptor tyrosine. Instead, RET may recognize other
structural features or conformations present within an intact
RET receptor that may be distal to the phosphoacceptor tyro-
sine. Alternatively, accessibility of the autoP tyrosines may be
controlled by conformational changes within RET ICD following
KD activation.
RET AL Y900 and Y905 Are Not De Facto Activating
Tyrosines
In thewell-established RTK paradigm, autoP of tyrosine residues
in the AL enhances catalytic activity and precedes the generation
of further phosphotyrosines sites within and outside the KD core.
These late autoP sites then serve as a platform for docking and
effectors proteins to transmit downstream signaling (Furdui
et al., 2006; Hubbard, 1997; Lew et al., 2009; McTigue et al.,
1999). However, our LFQMS data demonstrate that Y900 and
Y905 should not be considered ‘‘activating,’’ as their phosphor-
ylation display delayed kinetics (Figure 1) and they are neither
required for RET KD enzymatic activity (Knowles et al., 2006)
nor autoP (Plaza-Menacho et al., 2011). To test this further, we
analyzed the impact of single mutations Y900F and Y905F and
the double mutant Y900/905F on the timing of RET ICD autoP
(Figure 2A). Surprisingly, no significant effects on the levels
and kinetics of autoP were observed for either individual point
mutant or the double mutation compared to the wild-type (WT)
protein (Figure 2A). This is an interesting finding when compared
to a doublemutant Y900/Y905 in the context of the RET KD core,
which displayed severe defects in the autoP levels (Figure S3).
We then conducted enzyme kinetic experiments using a RET
peptide derived from the sequence containing the Y1015 autoP
site (Figure 2B). Against this peptide substrate, Y905, but not
Y900, was required for efficient RET kinase enzymatic activity;
in contrast to the data from the autoP assay where neither resi-
due was required for efficient RET autoP. These data suggest
that (1) peptides substrates are poor surrogates to assess RET
autoP, and (2) regions flanking the RET KD core influence kinase
activity and AL conformation, and deletion of these regions ex-
poses a dependency on AL phosphorylation lacking in the RET
ICD (see Figure S3).
RET ICD Lacking Individual AutoP Sites Is Functional
and Displays Small Changes in the Kinetics of AutoP
In order to assess the effect of each autoP site on the kinetics
and levels of RET autoP, we also generated baculoviruses
expressing RET ICD with the following mutants: Y687F, Y981F,Molecular Cell 53, 1–14, March 6, 2014 ª2014 The Authors 3
Figure 2. Phosphoacceptor Site Mutants Display Minimal Changes in the Pattern of RET AutoP
(A) WB analyses of recombinant purified RET ICD (2.5 mM) WT and the indicated Y to F mutants treated with ATP (5 mM) and MgCl2 (10 mM) for 0–120 min using
the indicated antibodies.
(B) Enzymatic assay performed with RET ICD WT, Y900F, Y905F, or the double mutant Y900/905F incubated with increasing concentrations of the RET Y1015
KRRDYLDLAS peptide. Data shown represent the mean (OD/min) ± SE, n = 4.
(C) Catalytic efficiency constants (kcat/KM) of (B).
(D–G) Dissection of Y1015 and Y1029 autoP by LFQMS analysis of recombinant purified RET ICD WT and Y1015F or Y1029F mutants (2.5 mM) treated with ATP
(5mM) andMgCl2 (10mM). Data represent themean signal value (Log2 ratios of phosphorylated peptides standardized to the nonphosphorylated counterparts) ±
SE, n = 4.
See also Figure S2 and Table S1.
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reveal significant changes in global terms of either specific or to-
tal levels of autoP (Figure 2A). As a control experiment, we tested
a catalytically impaired RET ICD K758M mutant. This mutant
could not undergo autoP upon ATP stimulation; however,
when employed as a substrate, it could be efficiently phosphor-
ylated (autoP ‘‘rescue’’) by a shorter version of RET comprising
the KD core (Figure S3).
Our initial LFQMS analysis did not discriminate between
Y1015 or Y1029 phosphorylation in the monophosphorylated
(1P) state of the peptide because of their proximity. The discrep-4 Molecular Cell 53, 1–14, March 6, 2014 ª2014 The Authorsancy between WB analysis using a phosphospecific Y1015 anti-
body and the mass spectrometry data, led us to investigate
further the temporal sequence of autoP for these two specific
sites. Using LFQMS we compared the kinetics of autoP of RET
ICD WT, Y1015F and Y1029F (Figures 2D–2G). When the 1P
phosphorylation status (regardless of which of the two sites)
was analyzed, we observed that both sites are required to reach
the optimal 1P state (Figure 2D). Both sites are also required
to achieve optimal di-phosphorylation (2P) status (Figure 2G).
Comparison of the kinetics and degree of autoP (Figures 2E
and 2F) demonstrated that Y1015 phosphorylation was an earlier
Figure 3. Oncogenic Mutations in the RET Tyrosine KD Perturb the AutoP Trajectory
(A) WB analysis of RET ICD (2.5 mM) WT and oncogenic mutants V804M and M918T stimulated with ATP (5 mM) and MgCl2 (10 mM) for 0–120 min using the
indicated antibodies.
(B) Quantitation by densitometry analysis of experiments depicted in (A). Data represent the mean signal value (percentage) ± SE, n = 6. For clarity, only Y905 and
Y1015 are depicted.
(C) Temporal autoP analysis by LFQMSof recombinant purified RET ICD (2.5 mM)WT, V804M, orM918T treatedwith ATP (5mM) andMgCl2 (10mM) for 0–10min.
Data represent the mean signal value (Log2 ratios of phosphorylated peptides standardized to the nonphosphorylated counterparts) ± SE, n = 2.
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phorylation, which reached (16-fold increase between 40 and
80 min). These data demonstrate that Y1015 autoP precedes
Y1029, despite both being required for full autoP. These data
corroborate the results obtained by WB analysis where we
observed phosphorylation of Y1015 at earlier stages than the
LFQMS results predicted.
Oncogenic Mutations in the RET KD Perturb the AutoP
Trajectory
Having uncovered the precise temporal sequence of RET WT
autoP, we hypothesized that oncogenic mutants targeting the
RET KD, in particular M918T, may alter the kinetics of autoP by
impacting on the conformation of the kinase. We thereforeengineered baculoviruses expressing two oncogenic mutants
targeting the KD, V804M a drug-resistant gatekeeper mutation
associated with FMTC and MEN2A, (Gibelin et al., 2004; Plaza-
Menacho et al., 2007a) and the most phenotypically aggressive
MEN2B-associated M918T (Santoro et al., 1995). M918 maps
to region beneath the AL referred to as the P+1 substrate-bind-
ing pocket (Hubbard, 1997). Time courses of RET autoP for the
V804M and M918T mutants revealed much faster autoP kinetics
for both oncogenic mutants compared to the native protein.
In particular, late autoP sites within the KD core of RET WT
(Y900, Y905, and Y981) become phosphorylated much earlier
(Figures 3A and 3B). Likewise, Y1015 displayed faster kinetics
and higher levels of autoP for the oncogenic mutants compared
with the native protein. Early autoP sites Y1062 and Y687,Molecular Cell 53, 1–14, March 6, 2014 ª2014 The Authors 5
(legend on next page)
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Table 1. Data Collection and Refinement Statistics
RET M918T: Ade RET WT: Ade
Data collection
Space group C 2 C 2
Cell Dimensions
a, b, c (A˚) 71.9, 70.6, 79.0 73.2, 69.1, 78.6
a, b, g () 90.0, 101.1, 90.0 90.0, 101.7, 90.0
Resolution (A˚) 40–2.11 40–1.65
(Outer resolution shell) A˚ (2.23–2.11) (1.68–1.65)
Rsym (%) 6.9 (18.0) 7.4 (67.1)
hI/sIi 7.4 (2.6) 4.8 (1.2)
Completeness (%) 99.0 (99.0) 90.8 (91.0)
Redundancy 5.1 (5.4) 1.8 (1.9)
Refinement
Resolution (A˚) 40–2.1 40–1.65
(Outer resolution shell) A˚ (2.21–2.11) (1.68–1.65)
No. unique reflections 22,084 46,229
Rwork 15.6 (19.0) 15.1 (26.3)
Rfree
a 19.0 (25.4) 17.7 (32.3)
No. atoms 2 710 2 571
Average isotropic B-factors (A˚2)
Protein 32.1 33.4
Ligand 51.5 32.6
Water 37.9 47.4
Rmsd
Bonds (A˚) 0.005 0.019
Angles () 0.90 1.82
Ramachandran plot (%)
(favored, allowed, disallowed)
98.4/1.6/0.0 98.7/1.3/0.0
Ade, adenosine; Rmsd, root-mean-square deviation.
aA total of 5% of the data were set aside to compute Rfree.
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tent with an elevated enzymatic activity for both mutants
(Figure 3A). Interestingly, RET M918T displayed some degree
of phosphorylation at specific sites at zero time point, indicating
that this oncogenic mutant overcomes endogenous insect cell
tyrosine phosphatases. Alternatively, this mutant may overcome
cis-inhibitory mechanisms of regulation or use a trans mecha-
nism for oncogenic activation. These results were validated by
LFQMS comparing phosphorylation status of WT versus onco-Figure 4. Crystal Structure of Phosphorylated RET KD with Two Distin
(A) Crystal structure of phosphorylated RET KD bound to adenosine at 1.65 A˚
secondary structure components involved in the GRL tether are depicted with d
(B) Detailed view from (A), showing the two GRL conformations. Secondary struc
(C) Superposition of phosphorylated (p) RET KD bound to adenosine structure (P
pFGFR2 kinase domain structure (PDB ID code 2PVF, yellow). Peptide and main
homologous residues for both structures are shown (color-coded letters RET kin
(D) WB analysis of RET ICD (2.5 mM) WT, E734A, R912A and I913A mutants stim
antibodies.
(E) Sequence alignment of RTKs showing secondary structure components and t
two independent clusters. Numbering corresponds to RET sequence.
(F) Quantification by densitometry analysis (ImageJ) of (D). Data shown are the m
See also Figure S4.genic mutants at zero and 10 min time points, which gave suffi-
cient temporal resolution to measure the rapid phosphorylation
kinetics of oncogenic RET (Figure 3C).
A Crystal Structure of Phosphorylated RET KD with Two
Discrete Glycine-Rich Loop Conformations Reveals a
Tethered Autoinhibited State
Despite several RET KD crystal structures solved with a number
of inhibitors and AMP (Knowles et al., 2006; Mologni et al., 2010),
the impact of ATP or ATP-analogs on RET KD conformation has
been elusive. During efforts to trap a RET KD structure in com-
plex with ATP, crystals took several months to grow. We deter-
mined the structure at 1.65 A˚ resolution and identified an aden-
osine moiety within the nucleotide cleft indicating a complete
hydrolysis of the ATP (Figures 4A and 4B; Table 1; Supplemental
Experimental Procedures). A striking feature of this RET KD
structure is the presence of two distinct conformations of the
glycine-rich loop (GRL) indicating the intrinsic flexibility of this re-
gion. In the ‘‘closed’’ conformation, the GRL is clamped over the
kinase cleft with F735 side chain packed against the aC helix and
the side chain of E734 from the GRL hydrogen bondings to the
side chain of AL residue R912, which also interacted with side
chain of D771 from the aC helix (Figure 4B). In the second
‘‘open’’ conformer the GRL pivots away from the AL and aC helix
and has a solvent accessible F735 side chain. The two different
GRL conformations are defined by the mutually exclusive
conformation of two residues, E768 from the aC helix and
F735 from the GRL (Figure 4B). F735 shifts by 5.4A˚ between
these conformers, facing away from the nucleotide cleft in
the open conformer and tucked into the cleft in the closed
state. In the closed conformer, the E768 side chain points
away from the cleft and forms hydrogen bonds with the
main chain of S765 at the top of the aC helix.
Superimposition of the RET KD-adenosine structure with the
closely related FGFR2 bound to an ATP analog and substrate-
peptide structure (Chen et al., 2007) reveals that the ‘‘closed’’
GRL conformation would clash with the b and g phosphates
from ATP. Therefore this conformer would reflect an apo-state
of the enzyme, as it does resemble the apo-FGFR2 KD structure
(Protein Data Bank [PDB] ID code 2PSQ), particularly residues
911–914 of the activation segment (equivalent to FGFR residues
663–666). In the presence of Mg-ATP and a phosphorylated AL,
this region of FGFR2 KD is reorganized to accommodate a sub-
strate peptide (PDB ID code 2PVF). The ‘‘open’’ GRL conformer,
however, would readily accommodate ATP (Figure 4C), such act GRL Conformations Reveals an Autoinhibited Conformation
(PDB ID code 4CKJ) displaying two distinct conformations of the GRL. Main
iscrete colors.
ture components as well as the crucial residues are depicted.
DB ID code 4CKJ, color-coded) and ATP-analog and substrate-peptide bound
secondary structure components are depicted. Peptide (dark gray color) and
ase, black letter FGFR2 kinase).
ulated with ATP (5 mM) and MgCl2 (10 mM) for 0–80 min using the indicated
he two identified networks of residues interacting via hydrogen bonds defining
ean (percentage) ± SE, n = 2.
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precedes the aC helix located above the GRL. These hydrogen
bonds are formed between the main chain carbonyls of F735,
E734 and G733 from the GRL and the side chain nitrogen of
N763 and K761 and the main chain nitrogen of K761.
A closer look at the ATP-occluded conformer reveals a
possible autoinhibitorymechanism (cis-inhibition) to block nucle-
otide binding and perturb substrate interaction, involving three
key structural elements: the GRL, AL, and aC helix (Figure 4B).
In the previously determined phosphorylated RET KD crystal
structures (PDB ID codes 2IVT, 2IVV, and 2IVU), phosphorylated
Y905 was stabilized via hydrogen bonds between the phosphate
group and the side chains of R770 (aC helix) and AL R897 and
K907, in contrast to the single tether found in other RTKs, e.g.,
R1155 in the activated IRK structure (that is structurally equiva-
lent to R897 in RET). The closed GRL conformer also displays
a second triad of tethered residues via salt bridge interaction
involving hydrogen bonds between E734 from the GRL, R912
from AL and D771 from the aC helix as described above (Figures
4B and 4E).
To functionally validate these structural findings, we per-
formed time course autoP assays with point mutants E734A,
R912A, and I913A, which we anticipated would favor a GRL
open conformation. We observed that mutation of these resi-
dues enhances the kinetics of autoP of sites located at the
juxtamembrane, C-tail regions, and AL, with the exception of
I913A (Figures 4D and 4F). Taken together, these structural
and biochemical data indicate that the closed conformer of the
GRL contribute to a cis autoinhibitory mechanism. Mutations
that release this tether have a gain-of-function effect as indicated
by the faster kinetics of RET autoP.
Structural and Biophysical Characterization of
Oncogenic RET M918T KD
To understand the oncogenic mechanism of RET M918T activa-
tion, we also determined the crystal structure of the RET M918T
KD bound to adenosine at 2.1 A˚ resolution (Figure S4; Table 1;
Supplemental Experimental Procedures). The oncogenic RET
M918T KD structure displayed several features not shared by
previously solved structures of the native KD (Figure 5A). TheFigure 5. Structural, Biophysical, and Biochemical Characterization of
(A) Crystal structure of oncogenic RET M918T KD at 2.1A˚ resolution (PDB ID c
secondary structure components, ligand adenosine, and important residues are
(B) Biophysical characterization of RET ICD WT and oncogenic M918T. IF (arbitra
WT, phosphorylated RET ICDWT, and RETM918T. Left inset: shows themelting t
temperature for oncogenic RETM918T. Right inset: depicts our proposed model o
(*) denotes W917.
(C) WB analysis of autoP rescue experiments in trans of catalytically impaired R
M918T using the indicated antibodies. Total levels of RET (both enzyme and RETK
(5 mM) and MgCl2 (10 mM) for 0–120 min, n = 2.
(D) WB analysis of autoP rescue experiments in trans of catalytically impaired RET
using the indicated antibodies. Total levels of RET were monitored by Coomassie
(E) Enzymatic assay performed with purified recombinant RET ICD WT, V804M, o
using 8 mg/ml ABL peptide (EAYAAPFAKKK). Data represent the mean (OD/min
(F) Catalytic efficiency constants (kcat/KM) of (E).
(G) Isothermal titration calorimetry profiles of ATP for RET ICD WT and M918T a
against the molar radio of ATP to protein is depicted. Note that a minor proportio
sequential-binding site(s) model, and the solid lines represent the best fit.
See also Figures S4, S5, and Table S1.AL was phosphorylated on both Y900 and Y905, compared to
the singly phosphorylated AL on Y905 observed in RET WT KD
structures (PDB ID codes 2IVV, 2IVT, and 2IVU). Furthermore,
T918 forms a network of hydrogen bonds with a water molecule
and main chain carbonyl from I913 and P914 (Figures 5 and
S4). Paradoxically, we also observed the ‘‘closed’’ GRL
conformer defined by the second cluster of tethered residues
via hydrogen bonds involving E734 from the GRL, R912 from
AL, and D771 from the aC helix (Figure 5A). Similar to native
RET, this GRL conformer is not competent for ATP binding and
despite its high activity in solution it appears in a cis-inhibited
state in the crystal. A clue to this apparent paradox may come
from the robust proteomic and biochemical characterization of
RET M918T in solution (Figure 3), where we show that late autoP
sites (i.e., AL tyrosines) become phosphorylated much earlier
than RETWT, which in turn can affect the balance between enzy-
matic activity and substrate presentation in the process of autoP.
We considered whether theM918Tmutation could impact on the
accessibility of the AL to be presented as a substrate to a second
RET kinase molecule in trans. By destabilizing an ‘‘AL-in’’
conformer, the M918T oncogenic mutation would increase the
exposure of phosphoacceptor tyrosine sites presented to the
catalytic cleft of another RET kinase molecule (Figure 5B). Bio-
physical characterization based on intrinsic fluorescence (IF)
and thermal denaturation assays were used to test the proposed
‘‘AL-out’’ model for enhanced substrate presentation in trans.
Conformational changes of the AL can be measured in solution
by IF differences taking advantage of a tryptophan (W917) situ-
ated next toM918within the P+1 loop at the end of the activation
segment (Figures 5B and S5). Indeed, RET M918T showed a
marked difference in IF with a greatly decreased intrinsic trypto-
phanfluorescence compared toRETWT (Figure 5B).We interpret
this large difference as showing that the W917 environment is
perturbed by M918T. Hence, W917 would be buried within RET
WT kinase (AL-in) and accessible within M918T (AL-out). This
would be in agreement with an enhanced intermolecular sub-
strate presentationbyoncogenicRETM918T. This is also consis-
tent with a reduced melting temperature (4C lower) for this
mutant measured by thermal shift assay when compared to
RET WT indicating a significantly less stable protein (Figure 5B).Oncogenic RET M918T
ode 4CKI). Closed-up view shows the GRL in the closed conformation. Main
depicted with discrete colors.
ry units [a.u.]) emission spectra (307–500 nm, excitation at 280 nm) of RET ICD
emperatures for the indicated proteins, showing a significantly lowered melting
f enhanced substrate presentation in trans by an ‘‘AL-out’’ conformer. Asterisk
ET K758M KD (substrate, 2 mM) by active RET ICD (2.5 mM) WT, V804M, and
758M substrate) weremonitored byCoomassie staining. Time course with ATP
K758M, RET K758M/V804M, or K758M/M918T ICD (1 mM) by RET KD (2.5 mM)
staining. Time course with ATP (5 mM) andMgCl2 (10 mM) for 0–120min, n = 3.
r M918T (2.5 mM) incubated with increasing concentrations of ATP (0–400 mM)
) ± SE, n = 4.
t pH 7.65 at 20C. The plot of the heat released (kcal) per mol of ATP added,
n of ATP may be converted to ADP via autoP. The data were fitted to a single
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Enzymatic and Substrate Presentation Properties
To assess whether oncogenic mutations in the RET KD enhance
the enzymatic properties of the receptor, we performed autoP
rescue experiments in trans using a catalytically impaired RET
K758M KD as substrate. In this experiment, comparison be-
tween active RET ICD WT, V804M, and M918T indicated that
oncogenic mutations in the KD enhance the catalytic properties
of RET (Figure 5C). These data recapitulate the results of the
autoP process in situ (Figure 3). Next, to investigate whether
oncogenic mutations in the KD also enhance the substrate pre-
sentation properties of the receptor, the reciprocal experiment
was performed. Here, catalytically impaired RET K758M ICD
with or without the V804M or M918T mutations were used as
substrates. AutoP rescue experiments in trans by RET KD re-
vealed the unexpected finding that oncogenic mutations in the
KD also enhance the substrate presentation of the receptor (Fig-
ure 5D). Next, we calculated the enzyme kinetic parameters of
the oncogenic mutants and native kinases for ATP (Figures 5E
and 5F). Enzyme activity assessed upon increasing concentra-
tions of ATP revealed that only RET M918T displayed increased
enzyme kinetics parameters as indicated by the higher catalytic
efficiency constant (kcat/KM). To test if the increased enzymatic
constants observed for M918T correlated with increased affinity
for ATP, we directly measured ATP binding by isothermal titra-
tion calorimetry (ITC) to establish the apparent dissociation con-
stants (Kd). We found the Kd values for RETM918Twere an order
of magnitude lower than RET WT (1.1 ± 0.9 and 14.3 ± 0.3 mM,
respectively) indicating a significantly tighter ATP affinity (Fig-
ure 5G; Table S1). The basis for this tighter binding is unclear,
but we note that several hydrophobic core side chains adopt
distinct rotamers from those in RET WT, which together with
the lower apparent melting temperature for M918T, may suggest
a greater dependence on ATP-binding to stabilize the C-spine of
the kinase (Figure S4). Taken together, these data imply that
oncogenic mutations in the RET KD perturb the autoP trajectory
by enhanced substrate presentation in trans and increased
nucleotide pocket occupancy for ATP in cis.
Mutations Disrupting the GRL Tether Do Not Affect the
Enzymatic Activity But Do Enhance the Substrate
Presentation Properties of RET
To uncover whether mutations disrupting the GRL tether
enhance the enzymatic properties of the receptor, we performed
autoP rescue experiments in trans using catalytically impaired
RET K758M KD as a substrate. In this experiment, quantitative
comparison between active RET ICD WT, E734A, R912A, and
I913A revealed no significantly enhanced enzymatic activity
(Figures 6A and S6). Next, we tested whether these mutations
enhanced the substrate presentation properties of the receptor;
again the reciprocal experiment was performed. Catalytically
impaired RET K758M ICD with or without the E734A or R912A
mutations were used as substrates. AutoP rescue experiments
in trans by RET KD revealed that contrary to the effect on enzy-
matic activity, tether mutations do enhance the substrate pre-
sentation properties of RET, presumably by releasing the AL
for presentation in trans (Figure 6B). To test this hypothesis, IF
and thermal denaturation assays were performed (Figure S5).10 Molecular Cell 53, 1–14, March 6, 2014 ª2014 The AuthorsGRL tether mutants exhibited an intermediate IF emission
pattern between RET WT (ordered AL, W917 buried, and high
IF) and oncogenic M918T (unfolded AL conformation, W917
exposed, and low IF). These data seemed also independent of
the binding of ATP, as indicated by the use of a kinase-impaired
version in analogous experiments (Figure S5). The stability of
these mutants by thermal shift assay was also measured and
found no significant differences compared with RET WT. These
data indicate that tether mutations can impact on AL conforma-
tion to enhanced substrate presentation, without affecting the
stability of the protein. Next we calculated the enzyme kinetic pa-
rameters for ATP for the described mutants and native kinases
(Figures 6C and 6D; Table S1). Enzyme activity assessed
upon increasing concentrations of ATP revealed no significant
increase in the enzymatic parameters as indicated by their
catalytic efficiency constants. To measure the impact of these
mutations on the affinity for ATP we used ITC, which showed
that none of these mutants, contrary to what we anticipated,
significantly affected the affinity for ATP as indicated by their
Kd constant values (Table S1). These data show that tether mu-
tations within the GRL or AL enable nucleotide binding without
affecting the enzymatic activity of the kinase but rather by
enhancing RET substrate presentation in trans. However, con-
trary to oncogenic mutations, they do not alter affinity for ATP
(occupancy). These data support and emphasize the unex-
pected enhanced autoP substrate explanation for oncogenic
RET kinase activation.
DISCUSSION
Despite the crucial biological and pathological implications of
RET in early development and neoplastic processes, the precise
molecular mechanisms for RET KD activation and oncogenic
deregulation have so far eluded definition. The current paradigm
for RTK activation is that binding of extracellular ligand promotes
rapid phosphorylation of the canonical AL to boost catalytic
activity, remove cis-inhibitory conformations and generate
effector-docking sites (Artim et al., 2012). Examples include
the IRK, FGFR2, TrkA, and Ror (Artim et al., 2012; Hubbard,
1997). In this study, we show that contrary to many RTKs the
earliest detectable autoP sites generated following RET activa-
tion map to regions flanking the KD core while those sites within
the AL of the RET KD only form at much later time points (Figures
1 and 7). One interpretation of these results is that the flanking
regions restrict access to AL tyrosine sites, as part of a repres-
sive allosteric interaction (Chan et al., 2003; Hubbard, 2004). In
such a scenario, juxtamembrane and C-tail tyrosine autoPwould
precede AL phosphorylation as part of a concerted ordered acti-
vation trajectory for RET. Arguing against such a concerted
mechanism controlling access to AL autoP sites is the observa-
tion that mutation of individual autoP sites does not impact
dramatically on kinase activation or perturb the overall pattern
of autoP. For instance, Y1062F and Y687Fmutants do not signif-
icantly affect the kinetics of Y905 autoP (Figure 2A). We cannot
exclude the existence of compensatory mechanisms between
the juxtamembrane and C-terminal regions, or redundancy
of adjacent autoP sites. A plausible alternative is amore stochas-
tic activation mechanism where sites might be preferentially
Figure 6. Mutations Disrupting the GRL Tether Do Not Affect the Enzymatic Activity but Enhance RETKinase Substrate Presentation In trans
(A) WB analysis of autoP rescue experiments in trans of catalytically impaired RET K758M KD (substrate, 2 mM) by active RET ICD (2.5 mM) WT, E734A, R912A,
and I913A using the indicated antibodies. Total levels of RET were monitored by Coomassie staining. Time course with ATP (5 mM) and MgCl2 (10 mm) for
0–120 min, n = 2.
(B) WB analysis of autoP rescue experiments in trans of catalytically impaired RET ICD K758M, K758M/E734A, or K758M/R912A as substrates (1.5 mM) by active
RET KD (2.5 mM) using the indicated antibodies. Total levels of RET were monitored by Coomassie staining. Time course with ATP (5 mM) and MgCl2 (10 mM) for
0–120 min, n = 3.
(C) Enzymatic assay performed with purified recombinant RET ICD WT, E734A, or R912A (2.5 mM) incubated with increasing concentrations of ATP (0–400 mM)
using 8 mg/ml ABL peptide (EAYAAPFAKKK). Data represent the mean (OD/min) ± SE, n = 4.
(D) Catalytic efficiency constants (kcat/KM) of (C).
See also Figures S5, S6, and Table S1.
Molecular Cell
Enhanced Substrate Presentation by Oncogenic RET
Molecular Cell 53, 1–14, March 6, 2014 ª2014 The Authors 11
Please cite this article in press as: Plaza-Menacho et al., Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by
Enhancing Substrate Presentation In trans, Molecular Cell (2014), http://dx.doi.org/10.1016/j.molcel.2014.01.015
Figure 7. A Proposed Model for RET (WT) Kinase cis-Regulation and
Oncogenic Perturbation of the AutoP Trajectory In trans
Inset: summary of changes to the autoP trajectory by oncogenic RET M918T
(quantified by LFQMS based on saturation rates). This is caused by an
enhanced enzymatic activity and higher affinity for ATP and the production of a
better intermolecular RET substrate. RET WT KD cis-regulation by a tether
affecting GRL and AL conformation leading to autoinhibition. An ATP-bound
conformer disrupts the GRL tether between E734 (GRL), R912 (AL), and D771
(aC helix) allowing ATP to access the active site (enzyme, active kinase) and
releasing the AL. This leads to phosphorylation in trans (autoP) of a RET kinase
presented as a substrate. Oncogenic RET M918T kinase is autoinhibited in cis
by the GRL closed conformer despite displaying enhanced phosphorylation
status. Enhanced ATP affinity favors an open GRL conformer and a more
active enzyme, which also displays enhanced substrate presentation by pro-
motingmore flexible ‘‘AL-out’’ conformers (X denotes in a nucleotide-free state
of a catalytically impaired RET kinase presented as a surrogate substrate for
autophosphorylation in trans).
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the phosphoacceptor site or spatially-close determinants. How-
ever, we show that the phosphorylation efficiency of autoP sites-
based peptide substrates does not recapitulate the sequence
of autoP using an intact RET ICD or KD substrate (Figure S2).
This argues that determinants influencing how rapidly sites are
targeted are not local to the tyrosine autoP site but appear
opportunistic relating to tyrosine site accessibility and location
within the kinase structure consistent with a highly active artifi-
cially ‘‘forced’’ RET dimer (Figure S6). Our data point toward
kinase regulation independent of AL phosphorylation but
determined by inputs from flanking regions and other structural12 Molecular Cell 53, 1–14, March 6, 2014 ª2014 The Authorsand functional components (e.g., GRL, aC helix) independently
of the autoP sites, because these would play a key role in dock-
ing and downstream signaling rather than being catalytically
required.
Our data confirm earlier reports (Knowles et al., 2006; Plaza-
Menacho et al., 2011) showing that RET-AL phosphorylation is
not a prerequisite for kinase activation. Precedents exist for AL
phosphorylation-independent RTKs such as the EGFR, c-Kit,
and ACK1 kinases (DiNitto et al., 2010; Lougheed et al., 2004;
Stamos et al., 2002; Zhang et al., 2006). In the case of EGFR,
activation of the KD is achieved independently of AL phosphor-
ylation by both overcoming steric constraints in the extracellular
region and promoting the association of transmembrane and
intracellular regions into a ligand-dependent asymmetric EGFR
dimer (Endres et al., 2013). Whether similar mechanisms operate
for RET activation independent of AL phosphorylation requires
further study, but it is suggested by our results.
The structural data presented here uncover a possible cis-
inhibitorymechanism connecting three crucial structural compo-
nents of the RET KD. In the closed GRL conformer, ATP access
to the nucleotide-binding pocket is restricted by the GRL being
tethered to the AL (Figures 4 and 7). The tether couples side
chains of E734 (GRL), R912 (AL), and D771 (aC helix) through
hydrogen bonds, a structural feature that was not seen in previ-
ous phosphorylated RET KD structures (Knowles et al., 2006).
These interactions explain a role for a GRL glutamate (i.e., RET
E734), an unusual feature in RTKs (Figure 4E). Mutations disrupt-
ing the GRL tether also perturb the autoP trajectory of RET in a
gain-of-function manner, in contrast to single Y/F mutants tar-
geting the autoP sites, which did not have a significant effect
(Figures 2 and 4). ATP-binding-site occlusion by unphosphory-
lated activation segments has been previously observed (Artim
et al., 2012). We propose that a tethered GRL to the AL and aC
helix conformation provides a distinct means to couple substrate
interaction and ATP cleft access reminiscent of, but distinct
from, the FGFR2 autoinhibitory ‘‘molecular brake’’ promoted
by the crosstalk between the kinase hinge region, aC helix and
AL (Chen et al., 2007).
A major focus of this study was to understand how onco-
genic RET V804M and M918T deregulate kinase activity
compared with RET WT. Comparison of oncogenic V804M
and M918T RET kinase mutants in autoP assays revealed
that late autoP sites become phosphorylated more rapidly
than for RET WT (Figures 3 and 7). We hypothesized that the
perturbation of the autoP trajectory could arise either by
increasing RET catalytic activity or by enhancing the presenta-
tion of RET as a substrate in trans, or both. In addition, it could
also affect the enzyme kinetics parameters and affinity of
the mutant kinase for ATP. We verified that oncogenic RET
M918T increases enzymatic activity and ATP affinity analogous
to the T790M mutation of the EGFR (Yun et al., 2008). The
structure of oncogenic RET M918T KD however also exhibited
a tethered GRL conformer indicating an occluded nucleotide-
binding pocket, or cis-inhibited state (Figure 5A). This led
us to question whether in solution, perturbation of the autoP
trajectory by RET M918T could arise through presentation of
a better intermolecular substrate by favoring an ‘‘AL-out’’
conformer presenting Y900 or Y905 as a substrate to an active
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between RET WT and M918T suggest that in solution the
conformational dynamics and flexibility of the AL are increased
by the oncogenic mutation. Similar studies for FGFR2 and Eph
RTKs have shown that kinase activation involves an increase in
the conformational dynamics of their respective ICDs (Chen
et al., 2013; Wiesner et al., 2006). Our biochemical evidence
suggests that the impact of M918T in a kinase-impaired sub-
strate is to generate a better substrate for phosphorylation in
trans. This unexpected facet of oncogenic RET M918T is in
addition to increasing RET enzymatic activity and ATP affinity
(Figures 5 and 7). We note that M918T also has increased ac-
tivity toward exogenous substrates and is itself phosphorylated
to a greater degree by exogenous kinases such as FAK (Fig-
ure S7). How M918T mutation perturbs the GRL cis-inhibition
in solution and increases ATP affinity is unclear from the
DFG-in conformer crystal structure. Solution data indicate a
change in stability and conformational dynamics, which could
affect the catalytic spine and thus ATP affinity (Figure S4).
Whether M918T could disrupt a DFG-out conformer in RET re-
mains to be shown. However, disruption of the GRL tether by
mutation selectively alters the autoP trajectory and increases
substrate presentation in trans without altering catalytic activity
or ATP occupancy (Figure 6).
In summary, our findings indicate that RET is a member
of a select group of RTKs whose kinase activity is regulated
by regions flanking the KD core rather than by AL phosphoryla-
tion. The slow time course for AL Y900/Y905 phosphorylation
may be crucial for signaling because of a role in effector re-
cruitment rather than as an activation event. AutoP in trans ap-
pears more complex than a simple recognition of primary
sequence motifs containing an accessible phospho-acceptor
site. Our data show that oncogenic RET mutations promote
autoP by both increasing catalytic activity and generating a bet-
ter intermolecular substrate. At the same time they introduce
greater flexibility, lower stability, and higher ATP affinity for the
kinase domain with important implications for oncogenic RET
chemical inhibition. This illustrates the subtlety and complex
effects a single point mutation can exert to perturb RTK activa-
tion mechanisms.
EXPERIMENTAL PROCEDURES
Full experimental details are found in the Supplemental Information.
Expression and Purification of Recombinant Protein
Protein expression was carried out using Sf9 insect cells infected with re-
combinant Baculoviruses as previously described (Knowles et al., 2006). Hu-
man RET9 ICD (residues 661–1,072) and KD core (705–1,013) WT and the
indicated mutants proteins were purified as previously described (Knowles
et al., 2006).
Mass Spectrometric Label-Free Quantitation
For label-free quantitation, three to five biological replicates and three tech-
nical replicates were analyzed per condition. Data was acquired using the Agi-
lent’s LC-Chip Cube-6520 QTOF in MS-only mode. MS data was recorded
with the settings required in profile mode with the exception of recording
one spectrum per second. Data was acquired randomly as determined by
list randomizer (http://www.random.org/lists/). Files were imported into Pro-
genesis LC-MS version 4.0.4573.30654 (Nonlinear Dynamics) for LC-MS runalignment and MS peak extraction for label-free quantitation after ion peak
identification by MASCOT. Peaks of interest were analyzed and validated
using Excel and Graph Pad.
AutoP Assays, SDS-Page, and WB
Unless otherwise indicated, time course autoP assays were performed with
recombinant purified RET ICD and/or KD core (2.5 mM) in the presence of
saturating concentrations of ATP (5 mM) and MgCl2 (10 mM) for the indicated
time points. Reactions were stopped by the addition of 43 loading sample
buffer (Invitrogen) with 10% b-mercaptoethanol and boiled for 5 min after
which samples were loaded on gel. Samples were run in a NuPAGE Invitro-
gen 4%–12% Bis-Tris precast gels, and WB was performed with the indi-
cated antibodies as previously described (Plaza Menacho et al., 2005,
2007a, 2007b). Details of antibodies used are in the Supplemental
Information.
Phosphospecific RET Y687 Antibody Generation
Polyclonal antisera against phosphorylated RET Y687 was generated
by immunizing rabbits with a synthetic peptide (AFPVSpYSSSGA) KLH-
conjugated via glutaraldehyde following a standard protocol (Pettingill
Technology).
Enzymatic Kinase Assays
Enzyme kinetic experiments were performed as previously described
(Knowles et al., 2006; Plaza-Menacho et al., 2011).
ACCESSION NUMBERS
The crystallographic coordinates and structure factors have been deposited in
the PDB (http://www.pdb.org). PDB ID codes for the RET WT and RET M918T
KD crystal structures are 4CKJ and 4CKI, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.molcel.2014.01.015.
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